BioCardia, Inc. (BCDA)
BioCardia, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
BioCardia, Inc. (BCDA) is a Biotechnology company based in US with a market capitalization of $4.9M. Free cash flow was negative at -$7.4M. This page tracks BCDA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 17 employees · IPO Nov 13, 1996
Valuation
Valuation & price
$1.01as of May 17, 2026· -55.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.51
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$4.9M
Market cap
—
Revenue growth (YoY)
-7463.8%
Gross margin
-$7.4M
Free cash flow (USD)
-$2M
Net debt
Net cash position
143.0%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.21)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 18, 2026Filing
Shareholder Update
- 8-K eventJun 12, 2026Filing
Compliance Update
- 8-K eventJun 8, 2026Filing
Share Sale Announcement
- 8-K eventJun 5, 2026Filing
FDA Meeting Minutes Received
- 8-K eventMay 28, 2026Filing
Regulatory Submission Support
- 8-K eventMay 21, 2026Filing
Clinical Trial Results
- Quarterly reportMay 15, 2026Filing
10-Q Filed
- 8-K eventMay 15, 2026Filing
Earnings Release
- 8-K eventMay 8, 2026Filing
FDA Meeting Outcome
- 8-K eventApr 28, 2026Filing
Patent Allowance
Questions
Frequently asked questions
What is BioCardia, Inc.'s market cap?
BioCardia, Inc. (BCDA) has a market capitalization of $4.9M.
What is BCDA's P/E ratio?
A meaningful P/E ratio is not available for BCDA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is BCDA's price-to-book (P/B) ratio?
BCDA trades at 5.51 times book value per share.
When did BioCardia, Inc. last report earnings?
BCDA last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying BCDA stock?
SEC Form 4 filings show no open-market insider buys at BioCardia, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.